Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies.

Morse N, Jamaspishvili T, Simon D, Patel PG, Ren KYM, Wang J, Oleschuk R, Kaufmann M, Gooding RJ, Berman DM.

Lab Invest. 2019 Jun 3. doi: 10.1038/s41374-019-0265-2. [Epub ahead of print]

PMID:
31160688
2.

PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.

Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Picanço de Albuquerque CG, Reis RB, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M.

Prostate. 2019 Jun;79(9):969-979. doi: 10.1002/pros.23808. Epub 2019 Apr 18.

PMID:
30999388
3.

The Proteogenomic Landscape of Curable Prostate Cancer.

Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, Fraser M, Kron K, Murison A, Lupien M, Sahinalp C, Collins CC, Tetu B, Masoomian M, Berman DM, van der Kwast T, Bristow RG, Kislinger T, Boutros PC.

Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005.

PMID:
30889379
4.

Operational immune tolerance towards transplanted allogeneic pancreatic islets in mice and a non-human primate.

Abdulreda MH, Berman DM, Shishido A, Martin C, Hossameldin M, Tschiggfrie A, Hernandez LF, Hernandez A, Ricordi C, Parel JM, Jankowska-Gan E, Burlingham WJ, Arrieta-Quintero EA, Perez VL, Kenyon NS, Berggren PO.

Diabetologia. 2019 May;62(5):811-821. doi: 10.1007/s00125-019-4814-4. Epub 2019 Jan 31.

PMID:
30701283
5.

Steroid-Free Immune Suppression Impairs Glycemic Control in a Healthy Cynomolgus Monkey.

Berman DM, Ruiz P Jr, Blandino-Rosano M, Bernal-Mizrachi E, Kenyon NS.

Cell Transplant. 2019 Mar;28(3):262-268. doi: 10.1177/0963689718823505. Epub 2019 Jan 24.

6.

Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.

Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM.

J Pathol. 2019 Apr;247(5):563-573. doi: 10.1002/path.5230. Epub 2019 Feb 20. Review.

PMID:
30604486
7.

Microencapsulated adult porcine islets transplanted intraperitoneally in streptozotocin-diabetic non-human primates.

Safley SA, Kenyon NS, Berman DM, Barber GF, Willman M, Duncanson S, Iwakoshi N, Holdcraft R, Gazda L, Thompson P, Badell IR, Sambanis A, Ricordi C, Weber CJ.

Xenotransplantation. 2018 Nov;25(6):e12450. doi: 10.1111/xen.12450. Epub 2018 Aug 17.

PMID:
30117193
8.

Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.

Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin J, Pond GR, Haider M.

Eur Urol. 2019 Feb;75(2):300-309. doi: 10.1016/j.eururo.2018.06.025. Epub 2018 Jul 13.

PMID:
30017404
9.

Paracrine Interactions within the Pancreatic Islet Determine the Glycemic Set Point.

Rodriguez-Diaz R, Molano RD, Weitz JR, Abdulreda MH, Berman DM, Leibiger B, Leibiger IB, Kenyon NS, Ricordi C, Pileggi A, Caicedo A, Berggren PO.

Cell Metab. 2018 Mar 6;27(3):549-558.e4. doi: 10.1016/j.cmet.2018.01.015.

10.

Clinical implications of PTEN loss in prostate cancer.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL.

Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review.

PMID:
29460925
11.

Erratum: Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.

Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman DM, Siemens DR.

Bladder Cancer. 2018 Jan 20;4(1):137. doi: 10.3233/BLC-189029.

12.

Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.

Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman DM, Siemens DR.

Bladder Cancer. 2017 Oct 27;3(4):259-267. doi: 10.3233/BLC-170120. Erratum in: Bladder Cancer. 2018 Jan 20;4(1):137.

13.

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

Patel PG, Selvarajah S, Guérard KP, Bartlett JMS, Lapointe J, Berman DM, Okello JBA, Park PC.

PLoS One. 2017 Jun 22;12(6):e0179732. doi: 10.1371/journal.pone.0179732. eCollection 2017.

14.

Bioengineering of an Intraabdominal Endocrine Pancreas.

Baidal DA, Ricordi C, Berman DM, Alvarez A, Padilla N, Ciancio G, Linetsky E, Pileggi A, Alejandro R.

N Engl J Med. 2017 May 11;376(19):1887-1889. doi: 10.1056/NEJMc1613959. No abstract available.

15.

Clinical Experience with Daptomycin in Pediatrics.

Namtu KC, Crain JC, Messina AF, Dumois JA, Berman DM.

Pharmacotherapy. 2017 Jan;37(1):105-108. doi: 10.1002/phar.1872. Epub 2017 Jan 6.

PMID:
27870104
16.

Isolation of Pancreatic Islets from Nonhuman Primates.

Berman DM.

Adv Exp Med Biol. 2016;938:57-66. doi: 10.1007/978-3-319-39824-2_5.

PMID:
27586422
17.

Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.

Patel PG, Selvarajah S, Boursalie S, How NE, Ejdelman J, Guerard KP, Bartlett JM, Lapointe J, Park PC, Okello JB, Berman DM.

J Vis Exp. 2016 Aug 21;(114). doi: 10.3791/54299.

18.

Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes.

Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC.

Cancer Metab. 2016 May 5;4:8. doi: 10.1186/s40170-016-0149-5. eCollection 2016.

19.

Bioengineering the Endocrine Pancreas: Intraomental Islet Transplantation Within a Biologic Resorbable Scaffold.

Berman DM, Molano RD, Fotino C, Ulissi U, Gimeno J, Mendez AJ, Kenyon NM, Kenyon NS, Andrews DM, Ricordi C, Pileggi A.

Diabetes. 2016 May;65(5):1350-61. doi: 10.2337/db15-1525. Epub 2016 Feb 25.

20.

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

Picanço-Albuquerque CG, Morais CL, Carvalho FL, Peskoe SB, Hicks JL, Ludkovski O, Vidotto T, Fedor H, Humphreys E, Han M, Platz EA, De Marzo AM, Berman DM, Lotan TL, Squire JA.

Virchows Arch. 2016 May;468(5):607-17. doi: 10.1007/s00428-016-1904-2. Epub 2016 Feb 9.

PMID:
26861919
21.

The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation.

Ladas EJ, Bhatia M, Chen L, Sandler E, Petrovic A, Berman DM, Hamblin F, Gates M, Hawks R, Sung L, Nieder M.

Bone Marrow Transplant. 2016 Feb;51(2):262-6. doi: 10.1038/bmt.2015.275. Epub 2015 Nov 16.

PMID:
26569091
22.

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.

Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM.

Clin Cancer Res. 2016 Jan 15;22(2):448-58. doi: 10.1158/1078-0432.CCR-15-0256. Epub 2015 Oct 7.

23.

Failure to Validate a Multivariable Clinical Prediction Model to Identify Pediatric Intensive Care Unit Patients at High Risk for Candidemia.

Fisher BT, Ross RK, Roilides E, Palazzi DL, Abzug MJ, Hoffman JA, Berman DM, Prasad PA, Localio AR, Steinbach WJ, Vogiatzi L, Dutta A, Zaoutis TE.

J Pediatric Infect Dis Soc. 2016 Dec;5(4):458-461. Epub 2015 Apr 29.

PMID:
26407259
24.

Surveys and Response Rates.

Berman DM, Tan LL, Cheng TL.

Pediatr Rev. 2015 Aug;36(8):364-6. doi: 10.1542/pir.36-8-364.

PMID:
26232466
25.

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J.

Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973. Review.

PMID:
26205340
26.

Outcomes of squamous histology in bladder cancer: a population-based study.

Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, Peng Y, Booth CM.

Urol Oncol. 2015 Oct;33(10):425.e7-13. doi: 10.1016/j.urolonc.2015.06.011. Epub 2015 Jul 18.

PMID:
26199176
27.

HES6 promotes prostate cancer aggressiveness independently of Notch signalling.

Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM.

J Cell Mol Med. 2015 Jul;19(7):1624-36. doi: 10.1111/jcmm.12537. Epub 2015 Apr 12.

28.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

29.

HER2 as a target in invasive urothelial carcinoma.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J.

Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.

30.

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.

31.

Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study.

Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, Booth CM.

Urology. 2015 Apr;85(4):791-8. doi: 10.1016/j.urology.2014.12.027. Epub 2015 Feb 7.

PMID:
25661830
32.

A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.

Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM.

J Pathol. 2015 Feb;235(3):478-89. doi: 10.1002/path.4472.

33.

Response to editorial comments to Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study.

Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM.

Int J Urol. 2015 Feb;22(2):172. doi: 10.1111/iju.12642. Epub 2014 Oct 23. No abstract available.

34.

Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study.

Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM.

Int J Urol. 2015 Feb;22(2):163-70. doi: 10.1111/iju.12611. Epub 2014 Sep 4.

35.

Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer.

Booth CM, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ.

BJU Int. 2015 Sep;116(3):373-81. doi: 10.1111/bju.12913. Epub 2014 Dec 29.

36.

Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia.

Wang DH, Tiwari A, Kim ME, Clemons NJ, Regmi NL, Hodges WA, Berman DM, Montgomery EA, Watkins DN, Zhang X, Zhang Q, Jie C, Spechler SJ, Souza RF.

J Clin Invest. 2014 Sep;124(9):3767-80. doi: 10.1172/JCI66603. Epub 2014 Aug 1.

37.

Identification of ALK gene alterations in urothelial carcinoma.

Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE.

PLoS One. 2014 Aug 1;9(8):e103325. doi: 10.1371/journal.pone.0103325. eCollection 2014.

38.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

39.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17.

40.

PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.

Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor H, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM.

Mod Pathol. 2015 Jan;28(1):128-137. doi: 10.1038/modpathol.2014.85. Epub 2014 Jul 4.

41.

Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study.

Booth CM, Siemens DR, Li G, Peng Y, Kong W, Berman DM, Mackillop WJ.

Clin Oncol (R Coll Radiol). 2014 Aug;26(8):506-14. doi: 10.1016/j.clon.2014.05.007. Epub 2014 Jun 20.

PMID:
24954284
42.

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE.

Cancer Med. 2014 Aug;3(4):835-44. doi: 10.1002/cam4.262. Epub 2014 May 21.

43.

Notch signaling in prostate cancer: a moving target.

Carvalho FL, Simons BW, Eberhart CG, Berman DM.

Prostate. 2014 Jun;74(9):933-45. doi: 10.1002/pros.22811. Epub 2014 Apr 16. Review.

44.

Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.

Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ.

Cancer. 2014 Jun 1;120(11):1630-8. doi: 10.1002/cncr.28510. Epub 2014 Apr 14.

45.

When is prostate cancer really cancer?

Berman DM, Epstein JI.

Urol Clin North Am. 2014 May;41(2):339-46. doi: 10.1016/j.ucl.2014.01.006. Epub 2014 Feb 21. Review.

PMID:
24725494
46.

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.

Clin Cancer Res. 2014 Apr 1;20(7):1873-83. doi: 10.1158/1078-0432.CCR-13-0759. Epub 2014 Jan 31.

47.

The management and outcome of spinal implant-related infections in pediatric patients: a retrospective review.

Messina AF, Berman DM, Ghazarian SR, Patel R, Neustadt J, Hahn G, Sibinga EM.

Pediatr Infect Dis J. 2014 Jul;33(7):720-3. doi: 10.1097/INF.0000000000000264.

PMID:
24463805
48.

The evolving understanding of microRNA in bladder cancer.

Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM.

Urol Oncol. 2014 Jan;32(1):41.e31-40. doi: 10.1016/j.urolonc.2013.04.014. Epub 2013 Aug 2. Review.

49.

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ.

Ann N Y Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review.

50.

A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.

Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.

Sci Transl Med. 2013 May 29;5(187):187ra71. doi: 10.1126/scitranslmed.3005688.

Supplemental Content

Loading ...
Support Center